https://sciex.com/content/SCIEX/na/us/en


Gain New Insights Into Human Spermatogenesis with this “Click & Easy” OneOmics Workflow

Dec 4, 2015 | Blogs, Life Science Research, Proteomics | 0 comments

A recent webcast by Charles Pineau, Director of Protim, IRSET, Rennes, France, demonstrates how you can use the OneOmics™ Platform as a “Click & Easy” workflow for integrating next-generation proteomics (NGP) data with next-generation sequencing (NGS) data. Dr. Pineau and his colleagues are interested in gaining new insights into human spermatogenesis and understanding the dialogue between germ cells and somatic cells. In previous research using rat samples, over 1400 unannotated transcripts were identified. Subsequent proteogenomic studies then showed that some of those transcripts encoded for novel proteins. The data analysis for that research was performed using the open source EMBOSS suite of tools. 

In the current study, the researchers were interested in analyzing human samples and developing a more simplified workflow for data analysis. Using the SCIEX TripleTOF® 6600, and the Illumina HiSeq 2500, over 1100 new potential transcripts were identified with more than 2 peptides at FDR < 1%. The OneOmics Platform was used for data processing and analysis. Compared with the previous open source EMBOSS suite of tools used in the rat studies, the OneOmics Platform was about 75x faster. Additionally, another major benefit using the OneOmics Platform was the relative ease with which the data could be analyzed compared with the previous workflow which required extensive user customization by writing scripts and formatting files. This enabled the researchers to focus on the biology rather than the complications associated with formatting datasets and transformation of files. Ongoing studies are taking a subset of candidates and validating them using MRM studies, qPCR, and immunohistochemistry.

Comment below to get a demo OneOmics today.

 

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial